LAG3 Expression in Triple Negative Breast Cancer

NARecruitingINTERVENTIONAL

Enrollment

128

Participants

Timeline

Start Date

November 18, 2022

Primary Completion Date

July 1, 2025

Study Completion Date

December 31, 2027

Conditions

Triple Negative Breast CancerImmune Checkpoint Inhibitor

Interventions

PROCEDURE

LAG-3 expression / immune checkpoint protein expression

Evaluate the tissue and blood before and after chemotherapy

Trial Locations (1)

RECRUITING

Ji-Yeon Kim, Seoul

All Listed Sponsors

lead

Samsung Medical Center

OTHER